Vertex Pharmaceuticals (VRTX) Revenue — Quarter Ended Sep 30, 2024
Revenue rose compared with the prior quarter. Revenue also increased compared with the same quarter last year.
Key takeaway
Quarter ended Sep 30, 2024 · FY2024 Q3
Revenue rose compared with the prior quarter. Revenue also increased compared with the same quarter last year.
Financial snapshot
Reported revenue, sequential change, year-over-year change, and trailing four-quarter revenue.
Quarter revenue
$2.8B
Revenue reported for this quarter.
Quarter-over-quarter
+4.8%
Change from the immediately preceding quarter.
Year-over-year
+11.6%
Change from the comparable year-ago quarter.
Trailing four quarters
$10.6B
Sum of the latest four reported quarters.
Quarterly revenue trend
The latest four reported quarters with year-over-year comparisons.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Dec 31, 2023 | $2.5B | +9.3% |
| Mar 31, 2024 | $2.7B | +13.3% |
| Jun 30, 2024 | $2.6B | +6.1% |
| Sep 30, 2024 | $2.8B | +11.6% |
Revenue performance
The reported revenue moved upward from the immediately preceding quarter. Compared with the same quarter one year earlier, revenue was also higher.
Quarterly comparison
Revenue exceeded the prior quarter's level and surpassed the year-ago quarter's level. The sequential and year-over-year comparisons both reflect positive direction.
What to watch
No specific risk or contextual driver is mentioned in the supplied filing commentary.